A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Intervention/treatment:
BARICITINIB (LY3009104)
Medical condition:
ATOPIC DERMATITIS
Protocol code:
I4V-MC-JAIX
Control number:
215122
Status:
Closed
Approved:
May 02, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03559270
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Chief Medical Officer
Organization
Eli Lilly and Company
Phone:
800-545-5979
Sponsor
ELI LILLY CANADA INC

Locations

Alberta

Alberta DermaSurgery Centre
Edmonton, Alberta, T6G 1C3
Beacon Dermatology
Calgary, Alberta, T3E 0B2
Kirk Barber Research
Calgary, Alberta, T2G 1B1

British Columbia

Dr. Chih-ho Hong Medical Inc.
Surrey, British Columbia, V3R 6A7
Enverus Medical Research
Surrey, British Columbia, V3V 0C6

Ontario

Allergy Research Canada Inc.
Niagara Falls, Ontario, L2H 1H5
K. Papp Clinical Research
Waterloo, Ontario, N2J 1C4
Kingsway Clinical Research
Etobicoke, Ontario, M8X 1Y9
Lynderm Research Inc.
Markham, Ontario, L3P1X2
Medicor Research Inc
Greater Sudbury, Ontario, P3A 1W8
Simcoderm Medical & Surgical Dermatology Centre
Barrie, Ontario, L4M 7G1
SKiN Centre for Dermatology
Peterborough, Ontario, K9J 5K2
The Centre for Dermatology
Richmond Hill, Ontario, L4B 1A5
XLR8 Medical Research
Windsor, Ontario, N8W 1E6
York Dermatology Center
Richmond Hill, Ontario, L4C 9M7

Quebec

Centre de Recherche Dermatologique de Quebec Metropolitain
Québec, Quebec, G1V 4X7
Innovaderm Research Inc
Montreal, Quebec, H2X 2V1

Results

See the results from the trial NCT03559270. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?